The chart below shows how CURI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CURI sees a -3.16% change in stock price 10 days leading up to the earnings, and a +1.01% change 10 days following the report. On the earnings day itself, the stock moves by +2.17%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Record Quarterly Pre-Cash Flow: We generated our highest ever quarterly adjusted pre-cash flow of $2.6 million, marking our eighth consecutive quarter of increased pre-cash flow.
Quarterly Revenue Comparison: Our revenue for the third quarter was $12.6 million compared to $12.4 million in the second quarter and $15.6 million a year ago, showing growth.
EBITDA Improvement Focus: Adjusted EBITDA improved by $3.5 million from last year, reflecting our focus on the bottom line.
Direct Subscription Revenue Growth: We grew our direct subscription revenue by 13% year-over-year, indicating strong customer retention and growth.
New Partnership Agreements: We executed many new partnership agreements in Q3 that offer long-term reliable and durable recurring revenue.
Negative
Quarterly Revenue Comparison: Revenue for the third quarter was $12.6 million compared to $12.4 million in the second quarter and $15.6 million a year ago.
EBITDA and Cash Flow Improvement: Adjusted EBITDA improved by $3.5 million from last year and our adjusted free cash flow improved by $5.6 million as we continued our intense focus on the bottom line.
Adjusted EBITDA Improvement: Adjusted EBITDA loss was $0.4 million in the third quarter compared to a loss of $3.9 million a year ago.
Marketing Expense Decline: Advertising and marketing expense was $3.6 million, a decline of 30% from $5.1 million a year ago, as we have continued to reduce partner marketing obligations.
Free Cash Flow Improvement: Adjusted free cash flow was $2.6 million in the quarter compared with negative $3 million a year ago.
CuriosityStream Inc. (CURI) Q3 2024 Earnings Call Transcript
CURI.O
1.26%